Funguria in Hospitalized Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by National Institute of Allergy and Infectious Diseases (NIAID).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00138502
First received: August 26, 2005
Last updated: August 26, 2010
Last verified: October 2007
  Purpose

The purpose of the study is to test the hypothesis that a subpopulation of patients with candiduria are at significant risk for disseminated disease and would benefit from treatment, while others are at low risk from complications and therefore require no antifungal therapy.


Condition
Candidiasis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: The Significance of Funguria In Hospitalized Patients

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment: 926
Study Start Date: September 2001
Estimated Study Completion Date: April 2005
Detailed Description:

This protocol will attempt to generate a detailed clinical profile of patients with funguria and identify subgroups of patients with funguria at high risk for candiduria and determine the relative risks for obtaining candiduria. In addition, it will look at identifying subgroups of patients with funguria at high risk for candidemia and identifying subgroups of patients with funguria at high risk for death. Finally, it will attempt to determine if funguria independently predicts fungemia or death. Data will be complemented by surveillance of a comparable population without funguria.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects with fungi isolated from the urine of any colony count.
  2. Patients seen at either Harbor-UCLA Medical Center or Cedars Sinai Medical Center.

Exclusion Criteria:

1. Persons with a previously positive urine fungal culture during the current hospital admission.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00138502

Locations
United States, California
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048
UCLA Center For Vaccine Research
Torrence, California, United States, 90509
Sponsors and Collaborators
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00138502     History of Changes
Other Study ID Numbers: 02-050
Study First Received: August 26, 2005
Last Updated: August 26, 2010
Health Authority: Unspecified

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Candidiasis, Funguria

Additional relevant MeSH terms:
Candidiasis
Mycoses

ClinicalTrials.gov processed this record on September 30, 2014